The best source for GLP-3 (retatrutide) research material is a vendor that publishes lot-specific COAs from an ISO/IEC 17025-accredited lab covering HPLC, mass spectrometry, and endotoxin testing, accepts credit cards, and uses strict research-use-only language. The guide concludes that COA type and lab credentials, not price or brand, determine sourcing risk. Retatrutide is not FDA-approved.
What is the best place to buy GLP-3 (retatrutide) online for research use?
The best source for GLP-3 (retatrutide) research material is a vendor that publishes lot-specific COAs from an ISO/IEC 17025-accredited lab covering HPLC, mass spectrometry, and endotoxin testing, accepts credit cards, and uses strict research-use-only language. The guide concludes that COA type and lab credentials, not price or brand, determine sourcing risk. Retatrutide is not FDA-approved.
The peptide research landscape is evolving fast, and GLP-3 has emerged as one of the more compelling compounds drawing serious attention from the scientific community. Whether you are sourcing for legitimate laboratory work or academic investigation, finding a reliable supplier is not simply a matter of convenience; it directly impacts the integrity of your research outcomes.
The problem is that the market is flooded with vendors making bold claims, and separating trustworthy sources from questionable ones requires a trained eye. Purity certifications, third-party testing, shipping reliability, and customer support all play critical roles in determining whether a vendor deserves your trust and your investment.
This guide was built specifically to help researchers like you cut through the noise. We have evaluated the best places to buy GLP-3 online based on criteria that actually matter in a research context. By the end of this list, you will know exactly which vendors meet the highest standards, what red flags to watch for, and how to make a confident, informed purchasing decision every time. Let’s get into it.
What Is GLP-3 (Retatrutide)? A Quick Disambiguation for Researchers
If you have spent any time searching for this compound online, you have almost certainly encountered both terms used as though they mean the same thing. They largely do, in practice, but the distinction is worth understanding before you evaluate any vendor.
Retatrutide is the International Nonproprietary Name (INN) assigned to the synthetic peptide compound. “GLP-3” refers to the glucagon-like peptide-3 receptor axis the compound engages. The conflation is now normalized across research communities and vendor listing pages alike; as recently as March 2026, Scientific American described retatrutide as an “experimental GLP-3 weight-loss drug” in its headline coverage of ongoing clinical trials. That mainstream validation confirms what search data already shows: researchers using either term are in the same procurement funnel, looking for the same compound.
The mechanistic profile is what makes retatrutide genuinely distinct. Unlike GLP-1 analogs such as semaglutide, which act on a single receptor, retatrutide is a triple agonist targeting GLP-1R, GCGR, and GIPR simultaneously. This three-receptor engagement produces a metabolic signal profile that is categorically different from any single- or dual-agonist compound. Vendor content written for GLP-1-specific peptides does not describe retatrutide’s mechanism adequately, which matters when you are designing a research protocol and need accurate compound-specific documentation.
From a procurement standpoint, the nomenclature question does not change the evaluation criteria. Retatrutide, marketed under the GLP-3 shorthand, is sold strictly for research use only by grey-market vendors, including glp-123.com. It carries no FDA approval for prescription use and should not be framed otherwise. Researchers must approach sourcing with that regulatory context in mind, particularly as enforcement activity across the grey-market peptide sector intensified significantly through 2025 and into 2026.
Understanding where GLP-3/retatrutide sits relative to GLP-1 and GLP-2 peptides is relevant to research design. It does not, however, alter the vendor evaluation criteria that determine where you should actually source it.
Why Vendor Selection for GLP-3 Is More Critical Than Ever in 2026
The research peptide market underwent a structural collapse between early 2025 and March 2026, and that collapse directly affects every researcher sourcing GLP-3 today. Understanding what happened, and why it matters to your procurement decisions, is not background reading; it is due diligence.
The supply vacuum is real and significant. Peptide Sciences, which held the largest revenue position in the grey-market research peptide sector, voluntarily shut down on March 6, 2026. The timing was deliberate; the company was generating an estimated $7.4 million in monthly sales as recently as December 2025 and closed ahead of anticipated federal enforcement action. That volume of demand does not evaporate. It redistributes, compressing supply chains at surviving vendors and creating quality-control pressure throughout the market.
The Peptide Sciences closure was not an isolated event. Amino Asylum was raided by the FDA in the same period, and at least seven additional vendors exited the market throughout 2025. The FDA had issued more than 50 warning letters across the peptide industry by September 2025, and by late 2025 the DOJ had moved beyond civil letters to criminal guilty pleas against grey-market distributors. A meaningful portion of the GLP-3 supply chain has collapsed within roughly a 15-month window, as detailed in vendor quality analysis published on LinkedIn.
Concentrated demand creates quality risk. When buyers have fewer alternatives, vendors absorbing displaced order volume face pressure to cut corners. Industry testing roundups, including work by ACS Labs and WuXi AppTec, found that roughly 15 to 20 percent of supplier-provided certificates of analysis show meaningful discrepancies when samples are run independently, with purity overstatement as the most common failure mode. For a compound like retatrutide, where research integrity depends on known concentration, that failure rate is material.
Compounding the problem is a rise in lookalike domain fraud. Impersonating established peptide vendors has become common enough that confirming you are on a legitimate vendor’s site is now treated as a discrete, named verification step in researcher evaluation checklists, per current vendor comparison resources. It is no longer a background assumption.
The combination of supply contraction, elevated quality variance, and escalating enforcement makes vendor selection for GLP-3 a materially higher-stakes decision in 2026 than it was 18 months ago.
The 5 Criteria That Separate Legitimate GLP-3 Suppliers from the Rest

Not all GLP-3 suppliers operate at the same standard, and in the current regulatory environment, the gap between a compliant, quality-focused vendor and a problematic one is not a minor inconvenience — it is a material research risk. These five criteria provide a defensible framework for evaluating any supplier before a purchase decision is made.
1. Independent Third-Party Batch Testing from an ISO/IEC 17025-Accredited Laboratory
Supplier-provided certificates of analysis carry an inherent conflict of interest, and the data supports treating them with skepticism. Industry testing roundups, including work conducted by ACS Labs and WuXi AppTec, found that roughly 15 to 20 percent of supplier-provided COAs show meaningful discrepancies when samples are run independently, with purity overstatement as the most common failure mode. The operative requirement is not simply “third-party tested” as a marketing claim; it is testing conducted by a named laboratory that holds ISO/IEC 17025 accreditation, which is the international standard confirming a lab’s technical competence and measurement validity. Before trusting any named external lab, researchers should independently verify that lab’s accreditation status against the ILAC MRA database. Vendors that use credentialed external labs rather than in-house testing earn higher placement in vendor quality rankings specifically because of this verifiable accountability structure.
2. Per-Batch, Publicly Accessible, Dated, and Lot-Specific COA Library
A single generic COA posted to a product page answers one question: did some batch of this compound once test at a stated purity? It does not answer the question that actually matters to the researcher: does the specific vial being shipped match that documentation? The operative verification check is whether a buyer can match the certificate number to the lot number printed on the physical vial. Per-lot disclosure is now the highest-weighted single criterion in vendor ranking content, and vendors that maintain a publicly accessible, dated, lot-specific COA library hold a genuine competitive advantage. Vendors unable or unwilling to provide lot-matched documentation should be treated as non-qualifying regardless of other factors.
3. GLP-Class Specific Triple Testing: HPLC, Mass Spectrometry, and Endotoxin
Retatrutide is a 39-amino-acid triple-agonist with significantly higher molecular complexity than shorter research peptides. That complexity requires a correspondingly rigorous analytical approach. HPLC purity confirmation establishes the percentage of the target compound relative to impurities. Mass spectrometry identity verification confirms the compound is actually what the label claims. Endotoxin and sterility testing confirms the material is free from bacterial contamination that would compromise research integrity. According to a 2026 buyer’s guide for research peptide sourcing, the combination of all three methods represents the current gold standard for this compound class, and vendors publishing named purity figures attached to named lots using all three methods are demonstrably more defensible than those relying on HPLC alone.
4. Credit Card Payment Acceptance as a Baseline Legitimacy Signal
Payment method has become a reliable proxy for vendor accountability in researcher communities and ranking aggregators alike. Credit card acceptance preserves chargeback recourse, creates a documented paper trail, and indicates the vendor has passed the merchant account underwriting process, which itself involves baseline business legitimacy verification. Vendors accepting only Zelle, cryptocurrency, or similar non-reversible payment methods are rated as higher risk because there is no consumer recourse if product quality, purity, or delivery fails. This criterion functions as a minimum threshold rather than a positive differentiator; its absence is disqualifying, while its presence confirms baseline accountability.
5. Consistent “Research Use Only” Language with Zero Therapeutic Claims
The regulatory environment as of 2026 makes this criterion more consequential than it has been at any prior point. The DOJ escalated enforcement against grey-market peptide distributors to criminal guilty pleas in late 2025, and the SAFE Drugs Act, introduced in early 2026, was specifically designed to close the “research use only” loophole for compounds biologically identical to FDA-approved drugs. Vendors whose websites include dosing guidance, weight-loss framing, or any language directed at human consumers are operating outside the RUO classification boundary and expose both themselves and their research customers to elevated legal risk. Compliant vendor language explicitly states that products are not intended to diagnose, treat, cure, or prevent any disease and have not been evaluated by the FDA. Researchers should audit not just product pages but the full site, including blog content and FAQs, before establishing a supplier relationship.
GLP-3 Vendor Comparison: How the Top Suppliers Stack Up
With the five evaluation criteria established, applying them to the four vendors currently active in the retatrutide research space produces a clearer picture of where each supplier stands and what tradeoffs researchers are accepting.
Peptide Partners
Peptide Partners is the most directly named GLP-3 competitor in current independent ranking content, and its credibility is built on a specific, quantified foundation that is difficult to dismiss. Across 78 independent Finnrick lab tests, its retatrutide was rated at 91% purity, placing it second out of 239 vendors evaluated. That figure is not a vendor-generated claim; it originates from third-party testing across a large sample size, which is precisely the kind of evidence that separates auditable credibility from marketing copy. Researchers evaluating Peptide Partners should request lot-specific documentation to confirm that published aggregate figures correspond to the specific batch they are purchasing, since aggregate rankings do not guarantee batch-level consistency.
FormBlends
FormBlends holds the top position on at least one major review aggregator, and its ranking is traceable to a specific documentation practice rather than general reputation. The vendor publishes per-batch, three-method lab data covering HPLC purity, mass spectrometry identity confirmation, and endotoxin sterility testing. This three-method standard is the most comprehensive testing disclosure posture currently documented in the grey-market peptide space, and it directly addresses the most common failure modes: purity overstatement, identity substitution, and sterility gaps. Researchers displaced by the Peptide Sciences closure will find FormBlends’ COA library particularly relevant, since Peptide Sciences had set a comparably high documentation bar before its March 2026 shutdown. The critical question for any researcher is whether FormBlends’ COA library is organized by lot number and dated at time of testing, rather than presenting a single undated document applied across multiple batches.
Koi Peptides
Koi Peptides holds the top ranking on two separate independent review sites, making it the most consistently cited top-ranked vendor across the current research landscape. The differentiating factor is external laboratory accreditation: Koi Peptides tests every batch at an ISO/IEC 17025-accredited laboratory and posts dated, lot-specific COAs tied directly to the tested inventory. ISO/IEC 17025 accreditation is the international standard for testing and calibration laboratory competence, meaning the lab’s methods and results are subject to independent audit rather than internal quality control only. Researchers should verify that COAs posted on the site include the accreditation certificate number and testing date, and that those documents correspond to the specific lot numbers available for purchase at time of order.
glp-123.com
glp-123.com’s position in this comparison rests on the same objective criteria applied to the three vendors above: the accessibility and completeness of its COA library for GLP-3/retatrutide specifically, the laboratory credentials behind those documents, and its current availability as a reliable supply option for researchers who lost access when Peptide Sciences and Amino Asylum exited the market. For researchers navigating a consolidated supply environment, consistent in-stock status and transparent batch documentation matter as much as aggregate rankings. Researchers should review glp-123.com’s published COAs for retatrutide directly, confirm the testing methodology and laboratory identity, and cross-reference lot numbers against current inventory before placing an order.
The broader takeaway across all four vendors is that published COA type and laboratory credentials, not price or brand recognition, are the variables that determine sourcing risk in 2026.
How to Read a GLP-3 COA: What Researchers Should Actually Verify
A Certificate of Analysis is only as useful as the researcher’s ability to interpret it. For retatrutide specifically, five verification checkpoints separate a credible COA from one that provides false assurance.
1. Mass Spectrometry Confirmation Against the 4,859 Dalton Baseline
Retatrutide has a molecular weight of approximately 4,859 daltons. Every legitimate COA for this compound should include a mass spectrometry result consistent with this value. Mass spectrometry is the primary method for confirming molecular identity; it tells you whether the compound in the vial is actually retatrutide or something else entirely. A deviation of even a few hundred daltons is a disqualifying result, indicating either a mislabeled product, a degraded sample, or a substituted compound. If a COA omits mass spectrometry data altogether, the molecular identity of the product is simply unconfirmed, regardless of what any other metric shows.
2. HPLC Purity: The 98% Standard and the 91% Floor
High-performance liquid chromatography purity, expressed as a percentage of the area under the curve, is the most widely cited quality metric on peptide COAs and also the most commonly overstated. Research-grade GLP-3 should show greater than 98% purity by this method. The 91% purity result publicly documented for Peptide Partners across independent Finnrick lab testing represents the current public floor benchmark. Any vendor reporting materially below 91% warrants serious scrutiny; any vendor claiming significantly above 98% without third-party verification should be viewed with measured skepticism given that roughly 15 to 20% of supplier-provided COAs show meaningful discrepancies on independent retesting. Impurity peaks on a chromatogram at unexpected retention times often indicate synthesis byproducts or degradation fragments that can affect research outcomes.
3. Endotoxin Results Below 1.0 EU/mg
Endotoxin testing is non-negotiable for any GLP-3 intended for injectable research applications. Results must be expressed in EU/mg (endotoxin units per milligram) and must fall below 1.0 EU/mg. Bacterial endotoxins, primarily lipopolysaccharides from gram-negative bacteria, are a primary contamination risk in peptide synthesis and can trigger serious inflammatory responses even at sub-lethal concentrations. A COA that omits endotoxin data entirely is an incomplete document, full stop. The absence of this result does not imply the compound passed; it means the compound was never tested, or that the testing result was withheld.
4. Lot Number and Date Matching
The lot number printed on the COA must match the lot number on the physical vial received. A COA without a lot-specific identifier cannot be considered valid documentation for any particular batch. Additionally, a COA dated more than 12 months before receipt does not confirm the condition of the product currently in hand; peptide degradation is time-dependent and storage-condition-dependent. Generic, undated, or non-lot-specific COAs are marketing documents, not quality assurance documents.
5. Third-Party Lab Verification via ILAC
Independent COAs carry meaningfully more evidentiary weight than supplier-generated documents. The testing laboratory should be identified by name, and that name should be verifiable through the ILAC (International Laboratory Accreditation Cooperation) database, where ISO/IEC 17025-accredited labs are publicly listed. Researchers can cross-reference a lab’s accreditation number directly through the ILAC portal. COAs from unnamed labs, labs with no public web presence, or labs that cannot be found in accreditation databases should receive the same level of skepticism as a product with no COA at all. The absence of an identifiable, accredited testing lab is a structural red flag that no purity number can overcome.
GLP-3 Vendor Red Flags: A Practical Checklist for Researchers
With the evaluation criteria and COA interpretation frameworks covered, the next step is knowing what to watch out for before committing to a vendor at all. The following five red flags have emerged as the most reliable disqualifying signals in the current research peptide landscape.
1. Payment Methods Are Crypto or Zelle Only, With No Credit Card Option
This is the single most widely cited legitimacy indicator across researcher communities, and for practical reasons. Vendors that accept only cryptocurrency or peer-to-peer transfers like Zelle deliberately eliminate any third-party dispute mechanism. If the product you receive does not match its documentation in purity, concentration, or identity, you have no chargeback pathway and no recourse beyond hoping the vendor responds to a complaint. Reputable vendors that accept credit cards are demonstrating, in a structurally verifiable way, that they are willing to stand behind their product claims. Per the Peptide Vendor Red Flags checklist for 2026, this payment structure functions as a direct proxy for accountability posture. Treat crypto-or-Zelle-only payment as a hard stop, not a minor inconvenience.
2. No Per-Batch COA Library, or COAs That Are Undated, Lot-Less, or Lab-Anonymous
Independent testing has found that roughly 30% of peptide samples from unregulated sources are mislabeled, improperly dosed, or contaminated. The 2026 benchmark, set by top-performing vendors, is a publicly accessible per-batch COA library with HPLC purity data, mass spectrometry identity confirmation, a named testing laboratory, and a traceable lot number. Supplier evaluation guidance for retatrutide specifically treats a generic or undated COA not as a minor documentation gap but as a disqualifying factor, given the number of vendors that now meet the full standard. If you cannot link the COA to the specific lot you are receiving, the document provides no meaningful assurance.
3. The Domain URL Does Not Exactly Match the Vendor’s Known Domain, or the Site Was Recently Registered
Lookalike domain fraud targeting peptide researchers has become a named, documented consumer risk in 2026. Fraudulent sites impersonating established vendors have proliferated specifically because researcher demand is high and buyers are often transacting quickly. Before entering any payment or personal information, verify the exact URL character by character, check the domain’s registration history using a WHOIS tool, and confirm the SSL certificate is valid and issued to the correct entity. A recently registered domain paired with a familiar visual design is a strong signal of impersonation.
4. Therapeutic, Clinical, or Human Use Claims Anywhere in the Product Listing
The FDA has issued more than 30 warning letters targeting vendors of unapproved GLP-adjacent products, and in August 2026, a federal judge sentenced a peptide company owner to 70 months in prison following criminal convictions that included forged laboratory certificates and products adulterated with undisclosed substances. Any vendor making dosing recommendations for human use, referencing clinical outcomes, or framing products as treatments is either uninformed about or indifferent to the operative legal framework. Consistent “research use only” language is not boilerplate; it is the legally required framing for this category.
5. No Identifiable Contact, No Verifiable Address, and No Forum History
Vendor anonymity compounds risk in a market where enforcement actions can end a supplier’s operations overnight without advance notice. Legitimate vendors maintain identifiable customer service contacts, verifiable business addresses, and visible, searchable histories on researcher communities such as Reddit’s r/Peptides or independent review aggregators. Anonymity removes every layer of accountability available to researchers when quality disputes arise or supply is unexpectedly interrupted.
GLP-3 Regulatory Status in 2026: What Researchers Need to Know
Understanding where GLP-3 sits within the current regulatory framework is not a peripheral concern for researchers. It is a foundational procurement decision that carries real legal and operational consequences in 2026.
The “Research Use Only” Status: Protected, Not Blanket-Exempt
Retatrutide currently exists in the grey market under a “research use only” (RUO) designation. It is not an FDA-approved prescription medication, and purchasing it for genuine laboratory research purposes is not illegal under that framing. However, researchers who interpret this status as broad legal protection are misreading it in a way that creates meaningful exposure. The FDA has made its position explicit, issuing warning letters tied to more than 20 violative products marketed under RUO and “not for human consumption” labels, stating these products have not been reviewed for safety, effectiveness, or quality. The RUO framing reduces regulatory exposure for researchers with documented, legitimate laboratory purposes; it does not eliminate it. Precision in how researchers characterize and document their use matters more now than at any prior point.
Legislative Pressure: The SAFE Drugs Act

Introduced in early 2026, the SAFE Drugs Act proposes to close the RUO loophole specifically for chemicals that are biologically identical to FDA-approved drugs. Retatrutide is not currently FDA-approved, which means it would not be directly captured under the Act’s current framing. That distinction, while meaningful today, should not invite complacency. The bill’s legislative intent signals growing Congressional attention to the entire GLP-class and research peptide product category. If retatrutide advances through its clinical trial pipeline toward approval, the compound’s legal status under this Act could shift rapidly. Researchers should monitor the bill’s committee progress as a leading indicator of near-term product availability.
DOJ Enforcement: A Structural Shift Researchers Cannot Ignore
The enforcement posture against grey-market peptide distributors changed materially by late 2025. The Department of Justice moved from civil warning letters, the prior standard tool, to pursuing criminal guilty pleas against grey-market distributors. This is not a marginal procedural change; it represents a fundamentally different risk calculus for both vendors and the researchers who source from them. Concurrently, the FDA issued a formal warning letter to Gram Peptides as recently as March 31, 2026, confirming that administrative enforcement remains active alongside the escalating criminal track.
A Favorable Parallel Track in the Compounding Space
Not all 2026 regulatory movement has tightened access. Following an HHS signal that the FDA had been overly restrictive, the agency removed 12 peptides from its Category 2 list for 503A compounding evaluation on April 22, 2026. An FDA advisory committee then voted on July 23 to 24, 2026, to recommend four peptides, specifically BPC-157, KPV, TB-500, and MOTS-C, for continued compounding access. A second advisory meeting covering additional compounds is expected before February 2027. This trajectory indicates the regulatory environment for peptides broadly is in active flux, with formal legitimization pathways opening for some compounds even as grey-market enforcement intensifies for others.
Practical Steps for Researchers Procuring GLP-3 Today
Researchers with legitimate laboratory purposes should treat compliance documentation as a non-negotiable operational baseline. Maintain clear records of research application, institutional context, and intended use. Source exclusively from vendors with transparent compliance postures, meaning those actively engaging with FDA guidance rather than relying solely on RUO labeling as a shield. Monitor SAFE Drugs Act legislative progress on a quarterly basis, as passage could affect product availability with limited advance notice. The researchers best positioned to continue their work without disruption are those who have already built the documentation infrastructure to demonstrate their procurement decisions were legitimate from the start.
Why Researchers Choose glp-123.com for GLP-3 Research Peptides
The criteria covered throughout this guide point toward one conclusion: when GLP-3 research is the specific application, a vendor built around the GLP peptide class carries structural advantages that general-catalogue suppliers cannot replicate.
Specialized Focus Translates to Deeper Quality Infrastructure
glp-123.com is built around GLP research peptides rather than distributed across dozens of unrelated compound categories. That specialization matters operationally. Testing infrastructure, sourcing relationships, and COA documentation protocols calibrated specifically to this peptide class produce more consistent batch-to-batch quality and more granular lot-level documentation than a vendor dividing quality resources across a broad, unfocused product library. For researchers who need GLP-3 data they can trust, that depth of compound-specific focus is a direct quality advantage.
Supply Availability in a Contracted Market
The post-Peptide Sciences landscape has concentrated retatrutide demand among a smaller pool of surviving vendors. Researchers who were displaced from their previous supplier in 2025 or early 2026 face a legitimate availability problem, not just a preference question. Before committing to any new vendor relationship, researchers should verify current GLP-3 batch availability at glp-123.com and confirm that lot-specific COA access is included with each order. Availability without documentation is not a viable research procurement option given the purity discrepancy rates documented across the broader market.
Third-Party Testing as the Non-Negotiable Proof Point
Independent COA data is the most credible quality signal available in this category. Researchers should review the active COA library at glp-123.com directly, evaluating testing methodology, the credentials of the laboratory used, and reported purity results against the benchmarks outlined earlier in this guide. Supplier-provided documentation alone is insufficient; the independent third-party testing standard applies here exactly as it does for any other vendor under consideration.
Baseline Trust Signals to Confirm Before Ordering
Credit card payment acceptance, consistent “research use only” labeling across all product pages, and accessible customer contact information are the minimum legitimacy markers researchers should verify as part of any new vendor onboarding. These signals are not sufficient on their own, but their absence is a hard stop regardless of other factors.
Researchers working through the comparison criteria in this guide will find that glp-123.com’s GLP-class focus positions it to meet the documentation depth and compound-specific sourcing standards that retatrutide research specifically requires. Apply the criteria, review the COA library, and let the documented evidence guide the decision.
Conclusion: Choosing a GLP-3 Vendor with Confidence
Selecting the right GLP-3 vendor in 2026 requires applying a consistent, evidence-based framework rather than relying on brand recognition that may no longer reflect market reality. The five criteria covered throughout this guide, specifically independent third-party testing, a per-batch COA library, triple-method verification combining HPLC, mass spectrometry, and endotoxin testing, credit card payment acceptance, and strict research use only language, represent the minimum standard a vendor must meet before a researcher places any order.
The market context reinforces why these standards cannot be treated as optional. With Peptide Sciences, Amino Asylum, and at least seven additional vendors no longer operating, outdated vendor lists and community recommendations based on 2024 experiences carry real procurement risk today.
As your immediate next step, access glp-123.com’s current GLP-3 batch availability, review the lot-specific COA library directly, and verify each testing credential against the benchmarks this guide has established.
Finally, monitor regulatory developments closely. The SAFE Drugs Act and the FDA advisory meeting anticipated before February 2027 could materially shift the framework governing GLP-3 research peptide availability within the next twelve months.
Frequently Asked Questions
Is GLP-3 the same as retatrutide?
In practice, yes. Retatrutide is the International Nonproprietary Name, and GLP-3 is the shorthand used on vendor pages and in search. Retatrutide is a triple agonist of GLP-1R, GCGR, and GIPR, whereas GLP-1 analogs such as semaglutide act on a single receptor.
What should a GLP-3 certificate of analysis show?
A credible retatrutide COA shows mass spectrometry consistent with roughly 4,859 daltons, HPLC purity above 98%, and endotoxin below 1.0 EU/mg. It should also carry a lot number matching the vial and a named lab verifiable through the ILAC database. A COA dated more than 12 months before receipt does not confirm current product condition.
What are the red flags when sourcing GLP-3 online?
The main red flags are crypto-only or Zelle-only payment, no per-batch COA library, and COAs that are undated, lot-less, or from anonymous labs. Others are a domain that does not exactly match the vendor's known site, therapeutic or human-use claims, and no identifiable contact, address, or forum history.
How common are inaccurate COAs from research peptide suppliers?
Testing roundups cited in the guide found roughly 15 to 20 percent of supplier-provided COAs show meaningful discrepancies when the material is independently retested. That is why a COA should be lot-specific, recently dated, and issued by a named lab whose accreditation can be checked, rather than accepted at face value.
Is it legal to buy GLP-3 for research purposes?
Retatrutide is sold under a research-use-only designation and has no FDA approval for prescription use. The guide says buying it for genuine laboratory research is not illegal under that framing, but the status is not blanket protection. FDA warning letters, DOJ criminal pleas, and the proposed SAFE Drugs Act show enforcement is tightening, so documentation of research use matters.
Originally published on glp-123.com. This library mirrors the guide for easier reading. Products mentioned are for laboratory research only.
View original



